BSEM Prepares for Nasdaq

What Investors Need to Know

April 20, 2026

*this email contains promotional content from BioStem Technologies, Inc.

BSEM Just Released Publication of Its Audited Financial Statements for Fiscal Years 2024 and 2025—Fast-Tracking a High-Profile Nasdaq Uplisting!

BioStem Technologies (OTCQB: BSEM) is rapidly evolving from a niche regenerative medicine innovator into a full-scale MedTech growth story. 

The company’s recent acquisition of BioTissue Holdings’ surgical and wound care business for up to $40 million not only broadens its market from physician offices into hospitals and surgical centers but also immediately adds $29 million in revenue and a seasoned national sales team. 

Coupled with the proven BioREtain® technology and breakthrough clinical results demonstrating superior wound closure rates, BSEM is now uniquely positioned to address a $300–$350 million total addressable market.

On the financial front, BSEM continues to impress. Q4 revenue topped $10 million with nearly best-in-class gross margins of 97%, and adjusted EBITDA remained solid at $3.4 million despite temporary headwinds. Importantly, the company has published its audited 2024–2025 financials, a key milestone toward its highly anticipated Nasdaq uplisting in 2026. 

This move promises increased liquidity, institutional investor interest, and higher valuation potential. With analysts assigning a $25.50 price target, BSEM’s combination of earnings strength, strategic expansion, and regulatory readiness underscores a rare small-cap investment story with multiple growth levers.

DISCLAIMER: This publication is owned and operated by Sherwood Ventures LLC (“SV”). Full disclaimer: https://bullseyealerts.com/disclaimer/.

NOT INVESTMENT ADVICE: We are a financial publisher, not a registered investment advisor. Content provided is for informational, educational, and promotional purposes only and should not be considered investment advice or a recommendation to buy or sell any security.

*PAID PROMOTION/COMPENSATION DISCLOSURE: SV has received six thousand dollars cash (via Sideways Frequency) for this one day program on 4/20/26 for marketing efforts to increase public awareness of BioStem Technologies, Inc. (BSEM). SV may have also previously been compensated for similar marketing efforts. As SV has received compensation from these companies, these parties have financial interests in the securities referenced. Further, SV and its affiliates may buy, sell, or hold positions in securities mentioned at any time without notice.

RISK WARNING: Investing involves substantial risk. Securities discussed may be highly speculative and volatile. Past performance is not indicative of future results, and you may lose some or all of your investment. Always consult a licensed financial professional before making investment decisions.